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Background: Over the last 10 years, endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) has become 
established as the first-line nodal staging procedure of choice for 
lung cancer patients. However, the pathway for patients following a 
negative EBUS-TBNA has not been clearly defined. The primary aim 
of this study was to develop and validate a risk stratification model 
to categorize lymph nodes deemed negative by EBUS-TBNA into 
“low-risk” and “high-risk” groups, where “risk” refers to the risk of 
false negative sampling.
Methods: A retrospective analysis of a prospectively maintained 
database at a UK tertiary EBUS-TBNA centre was performed. Only 
patients with primary lung cancer and only negative lymph nodes 
by EBUS-TBNA were included in the analysis. A risk stratification 
model was built from a derivation set using independent predictors 
of malignancy and the validation set used to evaluate the constructed 
model. The study period was from March 2010 to August 2013.
Results: Three hundred twenty-nine lymph nodes were included in 
the analysis (derivation set n = 196, validation set n = 133). Lymph 
node standardized uptake value, the standardized uptake value ratio 
between the lymph node and primary tumor, and heterogeneous echo-
genicity during sonographic assessment were the only independent 
predictors of malignancy. Using a simplified scoring system based 
on the natural logs of the odds ratios from the multivariable analysis 
on the derivation sample, lymph nodes can be stratified into low risk 
(score ≤1) and high risk (score ≥2). One hundred forty-one of 142 
and 94 of 96 lymph nodes classified as low risk in the derivation and 
validation set, respectively, were ultimately proven to be benign and 
35 of 54 and 24 of 37 lymph nodes classified as high risk were proven 
malignant. The negative predictive value of the risk stratification 
model for the derivation set and validation set was 99.3% (95% con-
fidence interval 96.1%–99.6%) and 97.9% (95% confidence interval 
92%–99.6%), respectively.
Conclusion: This risk stratification model may assist lung cancer 
multidisciplinary teams in deciding which patients need further stag-
ing procedures and which may proceed directly to treatment after a 
negative EBUS.
Key Words: Lung cancer, EBUS, EBUS-TBNA, Mediastinal stag-
ing, PET-CT.
(J Thorac Oncol. 2015;10: 126–133)
Treatment and prognosis in lung cancer is critically depen-dent on stage. In the absence of distant metastases the 
staging becomes dependent upon the presence or absence of 
regional lymph node involvement. Exclusion of N2/3 lymph 
node metastases allows identification of patients most likely to 
benefit from surgical resection and hence offer the best chance 
of long-term cure.1 Detection of N2/3 nodal metastases identi-
fies those patients that require multimodality therapy.2
Endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) has led to a paradigm shift in nodal 
staging pathways in the last 10 years, and is now widely avail-
able in the United Kingdom. It has been shown to be safer, 
cheaper than, and at least as effective as surgical nodal stag-
ing when used as the initial investigation of choice.3–9 Surgical 
staging, however, is still considered the standard procedure 
for nodal sampling. Indeed, National guidelines from both the 
United Kingdom and the United States recommend surgical 
staging in cases of negative EBUS-TBNA “where the sus-
picion of malignancy remains high.”10,11 A definition of high 
suspicion is not provided however. Furthermore, in a random-
ized control trial of endoscopic staging versus surgical stag-
ing, where every negative endoscopic procedure was followed 
by surgical sampling, 11 patients were required to undergo 
mediastinoscopy to identify one with N2/3 nodal metastases 
following a negative endoscopic procedure.12 Therefore, while 
the place of EBUS-TBNA as a first-line investigation for inva-
sive nodal staging is well established, the pathway for patients 
following a negative EBUS-TBNA is not. Considering that 
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negative EBUS-TBNA represents a significant proportion 
of all EBUS-TBNA staging procedures (an average of 40% 
in meta-analysis) and given the majority are truly negative 
(negative predictive value [NPV] 91%)11; if all patients with 
a negative EBUS-TBNA underwent surgical staging there 
would a significant number of futile surgical procedures with-
out adding any additional staging information. This could also 
lengthen the diagnostic pathway and delay definitive treat-
ment. Many authors, therefore, question the validity of surgi-
cal staging in all cases of negative EBUS-TBNA.6,7 Yet the 
characteristics that may identify which patients would benefit 
most from further staging have not been defined.
The primary aim of this study was to identify which 
characteristics may stratify the risk of nodal metastases in 
lymph nodes deemed negative following EBUS-TBNA. In 
other words, to provide a definition of “high suspicion” of 
malignancy that the national guidelines, described above, 
refer to. If lymph nodes can be accurately stratified into “low-
risk” and “high-risk”’ categories, where “risk” refers to the 
risk of false negative sampling, it may help lung cancer multi-
disciplinary teams (MDTs) to define which patients may need 
further surgical staging after EBUS-TBNA and those that may 
proceed directly to definitive treatment without further staging 
procedures.
PATIENTS AND METHODS
The University Hospital South Manchester (UHSM) 
provides a tertiary EBUS-TBNA service for a large Cancer 
Network in the North West of England. Prospective data are 
collected on all patients undergoing EBUS-TBNA and has 
been since its launch in March 2010. Patient demographics, 
referral and pathway data, and radiological characteristics are 
recorded before the procedure. Intraoperative findings, nodal 
sampling data, and complications are recorded following 
completion of the procedure and patient recovery. The patho-
logical results of EBUS-TBNA, the results of any subsequent 
nodal sampling, e.g., mediastinoscopy and the outcome of 6 
months of clinical–radiological follow-up are then added to 
the database when available. This study is a retrospective anal-
ysis of this prospectively maintained database.
Patient Selection
All patients referred to UHSM for EBUS-TBNA for 
nodal staging of suspected or confirmed lung cancer were 
reviewed. However, only patients with a pathological diag-
nosis of primary lung cancer or an MDT-agreed clinical 
diagnosis of lung cancer, such that definitive treatment was 
recommended, were included in the analysis. The reason for 
this was to simulate how we envisage a risk stratification pro-
cess being used in real life practice. The appropriate time to 
use this stratification would be when all minimally invasive 
staging results, both radiological and pathological, are avail-
able, most likely in an MDT setting. This prevents patients 
with benign disease or a low suspicion of lung cancer under-
going nodal staging stratification, when the focus of care may 
be elsewhere, such as further diagnostics or radiological fol-
low-up. Patients diagnosed with small-cell lung cancer were 
kept in the analysis as risk stratification in cases of negative 
EBUS-TBNA is relevant to this cohort of patients, as well as 
non–small-cell lung cancer (NSCLC) patients.
Nodal Characteristics
For every patient undergoing EBUS-TBNA, the follow-
ing information is collected for each lymph node sampled: 
size in short axis on computed tomography (CT), maximum 
standardized uptake value (SUVmax) of the primary tumor 
and SUVmax of the lymph node (in those patients under-
going positron emission tomography-computed tomogra-
phy [PET-CT] as part of their staging pathway) and lymph 
node appearances using endobronchial ultrasound. In 2010, 
Fujiwara et al.13 published the first analysis of lymph node 
appearances using endobronchial ultrasound. This large, 
retrospective study investigated five potential sonographic 
characteristics (Table 1), four of which were shown to be 
independent predictors of nodal metastases.13 The same five 
characteristics have been collected since the launch of EBUS-
TBNA at UHSM; echogenicity, shape, margin, central hilar 
structure, and coagulation necrosis sign.
Endobronchial Ultrasound-Guided 
Transbronchial Needle Aspiration
The accepted indications for EBUS-TBNA nodal stag-
ing at UHSM are: any hilar or mediastinal node with a short 
axis greater than 10 mm on CT, any abnormal fluorodeoxy-
glucose (FDg) activity in a hilar or mediastinal lymph node 
above that of the mediastinal blood pool and a central tumor 
with a normal mediastinum (defined as within the inner third 
of the thorax on transverse CT). Peripheral tumors with a nor-
mal mediastinum (defined as within the outer two thirds of the 
thorax on transverse CT) do not undergo pathological staging 
TABLE 1.  Definitions of the Sonographic Characteristics 
Used in the Assessment of Lymph Nodes During EBUS-TBNA
Sonographic Feature Description
Predictor of 
Malignancy
Echogenicity Homogeneous or 
heterogeneous 
appearance to the 
lymph node
Heterogeneous
Shape (oval vs.  
round)
Ratio of the short axis 
to the long axis of 
the lymph node
Round shape  
(ratio <1.5)
Margins (distinct vs. 
indistinct)
An echogenic border 
is visible between 
the lymph node and 
adjacent tissue
Distinct margin (>50% 
of the echoic border  
is visible)
Central hilar  
structure
A linear, hyperechoic 
area in the centre of 
the lymph node
Absence of the  
central hilar  
structure
Coagulation  
necrosis sign
A hypoechoic area 
without blood 
flow (representing 
necrosis), usually in 
the periphery of the 
lymph node
Presence of the 
coagulation  
necrosis sign
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration.
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and proceed straight to surgical resection assuming adequate 
fitness and the absence of distant metastases. EBUS-TBNA 
is performed under conscious sedation, using incremental 
doses of midazolam and alfentanyl, without anesthetic sup-
port. Standard diagnostic bronchoscopy is performed before 
all EBUS procedures using Olympus (BFF260 or BF6C260; 
Olympus, Southend-on-sea, Essex, United Kingdom) bron-
choscopes. EBUS-TBNA is performed using an Olympus 
BF-UC260FW ultrasonic bronchoscope and either 21- or 
22-gauge needles. A systematic examination of the mediasti-
num is performed and any lymph nodes that meet any of the 
following criteria are sampled: greater than 10 mm short axis 
on CT or during “real-time” ultrasound assessment, abnormal 
nodal FDg avidity above that of the mediastinal blood pool 
on PET or any abnormal ultrasound appearances according to 
the image classification system proposed by Fujiwara et al.13 
N3 nodes are sampled before N2 nodes followed by N1 nodes. 
Sampling of lymph nodes from the esophagus is not per-
formed and rapid onsite evaluation of samples is not available.
Statistical Analysis
The following characteristics were analyzed as poten-
tial predictors in a risk stratification model: lymph node size 
(mm in short axis on CT), lymph node SUV, SUV ratio (ratio 
between the SUV of the lymph node and the primary tumor, 
e.g., if the lymph node has a SUV of 3.0 and the primary tumor 
12.0 the ratio is 0.25, 25%), and sonographic characteristics 
(echogenicity, shape, margin, central hilar structure, and coag-
ulation necrosis sign). Individual lymph nodes were classified 
as “benign” or “malignant” based on the pathological results 
of EBUS-TBNA and any further pathological sampling plus 
6 months of clinical–radiological follow-up. A lymph node 
was only considered benign if all pathological results and 6 
months of follow-up failed to yield any evidence of malig-
nancy. The statistical analysis consisted of two stages. First, 
each individual characteristic was first assessed for its stag-
ing performance on the entire cohort of lymph nodes using 
standard definitions. To develop the risk stratification model 
only lymph nodes that were negative or inadequately sampled 
by EBUS-TBNA were used in the subsequent analysis. The 
decision to incorporate inadequate samples into the risk strati-
fication model allows all patients with no evidence of malig-
nancy from EBUS-TBNA to be incorporated. Furthermore, 
the classification of an EBUS-TBNA sample as inadequate is 
a subjective opinion by the reporting pathologist and objective 
definitions for inadequate sampling are lacking. All negative 
or inadequate lymph nodes were randomly divided accord-
ing to a 60%:40% ratio into a derivation set and a valida-
tion set. Logistic regression analysis was then applied to the 
derivation set to identify significant independent predictors of 
malignancy and then construct a prognostic index using the 
coefficients from the regression analysis which would give an 
optimal prediction score for malignancy. An appropriate score 
cutoff was then assessed. The validation sample was then used 
to evaluate the diagnostic accuracy of the constructed score.
In addition to the analysis described above, an interobserver 
agreement for the interpretation of ultrasound characteristics 
was performed. Two EBUS operators, blinded to the final lymph 
node pathology, were asked to interpret the ultrasound images 
recorded during EBUS for 50 lymph nodes. These were randomly 
selected by a computer program from the 329 negative or inad-
equate lymph nodes used in the risk stratification modeling. The 
data were summarized using frequencies, percentages and cross 
tabulations, and the percentage of observed overall agreement. In 
addition, the agreement was analyzed using Cohen’s Kappa statis-
tic. The analyses used the conventional two-sided 5% significance 
level. All summaries and analyses were produced using SPSS ver-
sion 20.
Sample Size
A formal sample size was not calculated but the power 
of the analysis is demonstrated by the CIs of the performance 
indicators (calculated using the Wilson method).
Study Period
The study period chosen was from March 2010 to 
August 2013. The analysis was undertaken in March 2014 
to allow 6 months of clinical–radiological follow-up for all 
lymph nodes.
RESULTS
Patient Characteristics
A total of 509 patients with lung cancer underwent 
EBUS-TBNA in the study period. All 509 patients underwent 
CT thorax before EBUS-TBNA and 72% (365 of 509) also 
underwent PET-CT in their staging work-up. The majority of 
patients had discrete enlargement of mediastinal lymph nodes 
on CT (74%, 376 of 509, CT N2/3) and abnormal FDg avid-
ity within mediastinal lymph nodes (86%, 313 of 365 PET-CT 
N2/3). Patient characteristics are presented in Table 2. The 
mean age was 70 years and 51% (261/509) were male. The 
majority were of good performance status (68%, 347 of 509 
performance status 0–1). Ultimately, 78% (396 of 509) were 
pathologically proven to have NSCLC, 5% (28 of 509) were not 
pathologically proven but treated under a clinical diagnosis of 
NSCLC and 17% were diagnosed with small-cell lung cancer. 
A total of 877 lymph nodes were sampled (1.7 per patient). 
The mean size of lymph node sampled was 17 ± 8 mm. Sixty-
six percent (337 of 509) of patients were ultimately staged 
with advanced nodal disease (N2/3) and 68% of lymph nodes 
sampled were ultimately proven to be malignant (596 of 877).
CT Nodal Staging
Of the 877 lymph nodes sampled with EBUS-TBNA, 
22% (190 of 877) were less than or equal to 10 mm and 78% 
(687 of 877) were greater than 10 mm. The mean size for 
benign lymph nodes was 11 ± 3 mm compared with a mean 
size of 19 ± 9 mm for malignant lymph nodes. One hundred 
thirty-seven of 190 lymph nodes measuring less than or equal 
to 10 mm on CT were ultimately classified as benign. Five 
hundred forty-three of 687 lymph nodes measuring greater 
than 10 mm on CT were ultimately classified as malignant. 
A lymph size greater than 10 mm in short axis on CT was 
associated with an increased risk of malignancy (OR 9.7, 
95% confidence interval [CI] 6.8–14.1). The performance 
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characteristics of CT nodal staging were as follows: sensitiv-
ity 91.1%, specificity 48.8%, NPV 72.1%, PPV 79.0%, and 
diagnostic accuracy 77.5%. The receiver operating character-
istic (ROC) curve demonstrates an area under the curve of 
0.843 (95% CI 0.816–0.869, Figure 1).
PET Nodal Staging–Lymph Node SUV
A total of 365 patients underwent PET-CT as part of 
their staging work-up, and 675 lymph nodes were sampled 
from these patients. The mean lymph node SUV was 7.3 ± 5.8. 
In those lymph nodes ultimately proven to be benign the mean 
SUV was 2.9 ± 1.2 compared with 10.1 ± 5.9 in malignant 
lymph nodes. A total of 564 lymph nodes were “PET posi-
tive,” defined as an SUV above that of the mediastinal blood 
pool, and 111 lymph nodes “PET negative.” Three hundred 
ninety-seven of 564 PET-positive lymph nodes were ulti-
mately proven to be malignant and 102 of 111 PET-negative 
lymph nodes proven benign. A lymph node SUV greater than 
that of the mediastinal blood pool was associated with an 
increased probability of malignancy (OR 26.9, 95% CI 13.3–
54.5). The diagnostic performance of PET-CT nodal staging 
in this study was as follows: sensitivity 97.8%, specificity 
37.9%, NPV 91.9%, PPV 70.4%, and diagnostic accuracy 
73.9%. The ROC curve demonstrates an area under the curve 
of 0.944 (95% CI 0.927–0.961, Figure 1). Following interro-
gation of the ROC curve a different “cutoff ” value to indicate 
“PET positivity” was analyzed. Using an SUV value greater 
than 4.0 to indicate PET positivity the diagnostic performance 
was as follows: sensitivity 89.9%, specificity 89.6, NPV 85.8, 
PPV 92.6%, diagnostic accuracy 89.8%, and OR 74.0 (95% 
CI 44.8–122.3).
PET Nodal Staging–SUV Ratio
For 673 lymph nodes it was possible to calculate the 
SUV ratio between the lymph node and the primary tumor, 
expressed as a percentage. The mean ratio was 65.8% ± 53.8%. 
In those lymph nodes ultimately proven to be benign the mean 
ratio was 26.7% ± 21.8% compared with 91% ± 53.0% in 
malignant lymph nodes. The ROC curve demonstrates an area 
under the curve of 0.928 (95% CI 0.907–0.950, Figure 1). 
Following interrogation of the ROC curve an optimal cutoff 
point was analyzed to indicate malignancy. Using an SUV 
ratio of greater than 40% to indicate malignancy the diagnos-
tic performance was as follows: sensitivity 90.9%, specificity 
86.6%, NPV 86.2%, PPV 91.1%, diagnostic accuracy 89.2%, 
and OR 64.1 (95% CI 34.1–104.4).
Endobronchial Sonographic Staging
A complete data set for ultrasound characteristics was 
achieved in 858 lymph nodes (98%, 858 of 877) and used in 
the analysis. The prevalence of benign and malignant lymph 
nodes stratified according each individual sonographic char-
acteristic is presented in Figure 1 and the diagnostic per-
formance of each characteristic in Table 3. Heterogeneous 
echogenicity (OR 123.0, 95% CI 64.8–233.6), round shape 
(OR 11.7, 95% CI 8.1–16.8), distinct margin (OR 1.4, 95% 
CI 1.1–1.9), the absence of a central hilar structure (OR 18.5, 
95% CI 10.8–31.7), and the presence of a coagulation necrosis 
sign (OR 50.4, 95% CI 7.0–363.7) were all associated with an 
increased risk of malignancy.
EBUS-TBNA Nodal Staging
A total of 877 lymph nodes were sampled with EBUS-
TBNA. Five percent (46 of 877) were deemed inadequate by 
the reporting pathologist. Nodal metastases were confirmed by 
EBUS-TBNA in 60% (525 of 877). Thirty-five percent (306 
of 877) of lymph nodes were classified as negative by EBUS-
TBNA and 16% (48 of 306) were subsequently proven to be 
false negatives. The performance characteristics of EBUS-
TBNA for nodal staging in this study were as follows: sen-
sitivity 91.6%, NPV 84.3%, and diagnostic accuracy 94.2% 
(specificity and PPV are assumed to be 100%). The verifica-
tion method for the final lymph node pathological diagnosis 
in cases of negative or inadequate lymph node sampling was 
TABLE 2.  Patient Characteristics
Age (mean ± SD) 69.9 ± 9.6
Sex, n (%)
  Male 261 (51.3)
  Female 248 (48.7)
Performance status (n = 509), n (%)
  0 84 (16.5)
  1 263 (51.7)
  2 131 (25.7)
  3 29 (5.7)
  4 2 (0.4)
Histological subtyping (n = 509), n 
(%)
  Adenocarcinoma 195 (38.3)
  Squamous cell carcinoma 165 (32.4)
  NSCLC “not otherwise specified” 27 (5.3)
  Large cell carcinoma 9 (1.8)
  Clinical diagnosis of NSCLC 
(without pathological confirmation)
28 (5.5)
  Small-cell lung cancer 85 (16.7)
Final nodal staging (n = 509), n (%)
  N0 112 (22)
  N1 60 (11.8)
  N2 246 (48.3)
  N3 91 (17.9)
Lymph node stations sampled with 
EBUS-TBNA (n = 877), n (%)
  High right paratracheal (2R) 29 (3.3)
  High left paratracheal (2L) 1 (0.1)
  Retrotracheal (3p) 8 (0.9)
  Low right paratracheal (4R) 256 (29.2)
  Low left paratracheal (4L) 123 (14.0)
  Subcarinal (7) 285 (32.5)
  Right hilar (10R, 11R) 106 (12.1)
  Left hilar (10L, 11L) 69 (7.9)
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; 
NSCLC, non–small-cell lung cancer.
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surgical sampling in 49% (174 of 352) and clinical–radiologi-
cal in 51% (178 of 352).
Risk Stratification Model in Negative 
or Inadequate Lymph Nodes
From the total sample of 877 lymph nodes, 352 were 
classified as negative or inadequate by EBUS-TBNA. Of 
these, 329 lymph nodes had complete data for every poten-
tial predictive characteristic. These 329 lymph nodes were 
randomly divided according to a 60:40 ratio into a derivation 
set (n = 196) and a validation set (n = 133). The derivation 
set contained 36 malignant lymph nodes (18%), and the vali-
dation set contained 26 malignant lymph nodes (19%). The 
logistic regression analysis performed on the derivation set is 
presented in Table 4. The coagulation necrosis sign was not 
included in the analysis because there were too few lymph 
nodes with this feature present to enable a reasonably robust 
regression analysis with this factor. Lymph node SUV, SUV 
ratio, and echogenicity were independent predictors of nodal 
metastases. Using a simplified scoring system (Table 5) based 
on the natural logs of the odds ratios from the previous mul-
tivariable analysis on the derivation sample, lymph nodes can 
be stratified into low risk (score ≤1) and high risk (score ≥2). 
In the derivation set, 142 lymph nodes were classified as low 
risk and 99.3% (141 of 142) were ultimately proven to be 
benign (NPV 99.3%, 95% CI 96.1–99.6). Fifty-four lymph 
nodes were classified as high risk and 64.8% (35 of 54) were 
ultimately proven to be malignant (positive predictive value 
[PPV] 64.8%, 95% CI 52%–76%). The sensitivity of this scor-
ing system on the derivation set was therefore 97.2% (35 of 
36, 95% CI 86%–100%) and the specificity 88.1% (141 of 
160, 95% CI 82%–92%).
The same scoring system was applied to the valida-
tion set of 133 lymph nodes. Ninety-six lymph nodes were 
classified as low risk and 97.9% (94 of 96) were ultimately 
proven to be benign (NPV 97.9%, 95% CI 92%–99.6%). 
FIGURE 1.  Ultrasound characteristics stratified by 
lymph node pathology, benign versus malignant.
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Thirty-seven lymph nodes were classified as high risk and 
64.9% (24 of 37) were ultimately proven to malignant (PPV 
64.9%, 95% CI 49%–78%). The sensitivity of the scoring 
system in the validation set was 92.3% (24 of 26, 95% CI 
76%–98%) and the specificity 87.8% (94 of 107, 95% CI 
80%–93%).
Interobserver Agreement for 
Ultrasound Characteristics
The strength of agreement between operators was “very 
good” for all characteristics except “margin” (Table 6). In 
particular, the observed agreement for echogenicity, the only 
ultrasound characteristic to be an independent predictor of 
nodal malignancy in multivariate analysis, was 93% (kappa 
0.86, 95% CI 0.7–1.0, p < 0.001).
DISCUSSION
It has been well documented that lymph size on CT is 
a poor predictor of nodal metastases in lung cancer.11,14 It is 
therefore unsurprising to find similar results in this study. The 
limitations of PET-CT in nodal staging are also well docu-
mented and consistent with our results. However, previous 
studies have investigated alternative methods of PET-CT inter-
pretation, just as this study has. Bryant et al.15 prospectively 
examined 397 patients under assessment for surgical resection 
of primary lung cancer in a single centre. The SUVmax of 
lymph nodes was evaluated against the pathological diagno-
sis and using a lymph node SUVmax cutoff of greater than 
or equal to 5.3 to predict nodal metastases achieved a sen-
sitivity of 91% and specificity of 88%.15 The SUV ratio was 
first investigated by Cerfolio et al. in patients with NSCLC 
and an SUVmax within at least one mediastinal lymph node 
of greater than 2.5. The prevalence of nodal malignancy in 
this study was 78%. The mean SUV ratio in malignant lymph 
nodes was 58% compared with 40% in benign nodes. The 
authors reported an area under the curve of 0.79, a sensi-
tivity of 94%, and a specificity of 72% when a ratio cutoff 
TABLE 4.  Logistic Regression Analysis on Derivation Sample 
(n = 196) to Predict Malignancy
Univariate Analysis Multivariable Analysis
OR  
(95% CI) Significance
ORa  
(95% CI) Significance
Echogenicity
  Homogeneous  
 (ref)
1 p < 0.001 1 p < 0.001
  Heterogeneous 135 
(40–454)
48  
(8–282)
SUV
  ≤4 (ref) 1 p < 0.001 1 p = 0.007
  >4 60  
(20–177)
10  
(1.9–59)
Lymph SUV%
  ≤40 (ref) 1 p < 0.001 1 p = 0.001
  41–60 32  
(9–115)
9  
(1.2–71)
  >60 81  
(23–287)
46  
(5–379)
Size
  ≤10 mm (ref) 1 p = 0.002
  >10 mm 4.0  
(1.7–9.8)
Shape
  Oval (ref) 1 p < 0.001
  Round 21  
(5–92)
Margin
  Distinct (ref) 1 p = 0.57
  Indistinct 1.2  
(0.6–2.6)
CHS
  Present (ref) 1 p = 0.005
  Absent 18  
(2–137)
aAdjusting for all other factors in the multivariable model.
CI, confidence interval; SUV, standardized uptake value.
TABLE 5.  Lymph Node Scoring System for Predicting 
Malignancy in Patients Not Found Malignant by EBUS-TBNA
0 1 2
Echogenicity Homogeneous Heterogeneous
SUV ≤4 >4
Lymph SUV% ≤40 41–60 >60
Total score varies between 0 and 5.
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; 
SUV, standardized uptake value.
TABLE 6.  Analysis of Interobserver Agreement for 
Ultrasound Characteristics
Observed 
Agreement Kappa 95% CI p Value
Strength of 
Agreement
Echogenicity 93% 0.86 0.7–1.0 <0.001 Very good
Shape 93% 0.85 0.69–1.0 <0.001 Very good
Margin 69.8% 0.4 0.13–0.67 0.007 Fair
CHS 95.3% 0.89 0.74–1.0 <0.001 Very good
CNS 95.3% 0.83 0.6–1.0 <0.001 Very good
CHS, central hilar structure; CNS, coagulation necrosis sign.
TABLE 3.  Diagnostic Performance for Each Ultrasound 
Characteristic
Characteristic
Sensitivity  
(%)
Specificity 
(%)
NPV  
(%)
PPV  
(%)
Accuracy 
(%)
Echogenicity 83.4 96.1 73.8 97.8 87.5
Shape 90.5 55.2 73.8 80.6 78.9
Margin 60.7 48.0 37.3 70.6 56.5
CHS 97.1 35.9 88.6 75.7 77.0
CNS 15.3 99.6 36.4 98.9 42.9
NPV, negative predictive value; PPV, positive predictive value; CHS, central hilar 
structure; CNS, coagulation necrosis sign.
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for malignancy of greater than or equal to 56% was used.16 
Koksal et al.17 subsequently undertook a retrospective review 
of 100 lymph nodes from NSCLC patients that had undergone 
surgical resection and lymph node dissection. The prevalence 
of nodal malignancy was low at 14% (14 of 100). The authors 
reported an area under the curve of 0.72 for the SUV ratio 
and if a cutoff of 20% was used a sensitivity of 93% and a 
specificity of 47% was achieved.17 In our study, using an SUV 
cutoff of greater than 4.0 and SUV ratio greater than 40% 
the diagnostic performance was excellent and improved the 
specificity of PET-CT from 38% to approximately 90% while 
maintaining good sensitivity (86%–89%). The prevalence of 
malignancy in our study was 68% and the results are similar 
to those reported by Cerfolio, in which the prevalence of nodal 
malignancy was similarly high.
In our study, echogenicity was the strongest sonographic 
predictor of nodal malignancy from Fujiwara’s proposed 
EBUS image classification system. It was the only sono-
graphic characteristic that proved to be an independent pre-
dictor of malignancy on multivariate analysis. Further studies 
on sonographic characteristics been published after this study 
began, the results of which are conflicting. Wang Memoli et al. 
prospectively evaluated the sonographic characteristics in 227 
lymph nodes from 100 lung cancer patients undergoing EBUS 
staging.18 Only lymph node shape was found to be predictive 
of nodal metastases, with no predictive power from margin 
or echogenicity. There was no interobserver analysis for this 
study however. A further prospective study by Schmid-Bindert 
et al.19 investigated shape, margin, echogenicity, central hilar 
structure, and the color power Doppler index in 281 lymph 
nodes from 145 patients. The strength of this study was the 
surgical verification of lymph node pathology in 148 of 162 
lymph nodes that were negative by EBUS-TBNA and a robust 
analysis of interobserver interpretation. As in our study, echo-
genicity was the best performer with 85% of heterogeneous 
lymph nodes proven to be malignant. The color power Doppler 
index showed both poor predictive power for nodal metastases 
and only moderate agreement between operators. In contrast, 
Nakajima et al.20 reported more promising results using the 
power Doppler mode in a retrospective study of 100 patients 
and, most recently, the first preliminary report for endobron-
chial ultrasound elastography, described as computer-assisted 
palpation, has been published.21
Regardless of these findings, this study was not designed 
to investigate the utility of radiological methods for nodal 
staging, through CT, PET-CT, or ultrasound. Radiological 
staging will never replace pathological staging. However, in 
cases of negative or inadequate EBUS-TBNA sampling, this 
study demonstrates the combination of PET-CT data and 
ultrasound data can stratify patients into high risk and low risk 
for nodal malignancy. Lymph nodes stratified as low risk by 
this stratification model have between a 98% and 99% chance 
of being truly negative based on our validation and derivation 
sets, respectively. The lowest value in the confidence inter-
val of either calculation was 92%, higher than the NPV of 
EBUS-TBNA alone (84%). The PPV is approximately 65% 
in both cohorts. This is due to the cutoff score chosen to sepa-
rate high risk and low risk and is a necessity to maintain such 
a high NPV. It is surely better to undertake mediastinoscopy 
and find benign lymph nodes than proceed with inappropriate 
radical treatment due to undetected malignant nodes. There 
are a number of discussion points when considering these 
results. First, this analysis is based on a per lymph node basis 
whereas much of the EBUS-TBNA literature is reported on a 
per patient basis. The denominator for per patient outcomes is 
the presence or absence of N2/3 nodal metastases. However, at 
our centre, single station or single zone N2 is managed differ-
ently form multistation N2, with surgical resection followed 
by adjuvant chemotherapy preferred to concurrent chemora-
diotherapy. We believe, therefore, EBUS nodal staging must 
accurately diagnose the nodal metastases within the single 
station N2 nodes and exclude metastases at other N2/3 nodes. 
To reflect the success or failure of this requires a per lymph 
analysis. In addition, there will frequently be differing SUVs 
and ultrasound characteristics within the same patient, again 
necessitating each individual lymph node to be considered 
independently for risk stratification. Second, the verification 
method in our study is suboptimal with only 49% of negative 
lymph nodes verified surgically. In an ideal world, all nodes 
would have been surgically verified but in the real world this 
is not possible. Many patients will not be fit for surgical proce-
dures, indeed 32% of patients were PS of greater than or equal 
to 2, and many go on to have oncological management that 
lacks any surgical involvement. Finally, but most importantly, 
there are limitations to consider in terms of which lymph 
nodes were sampled during EBUS procedures and the quality 
of the staging technique undertaken with EBUS. This study 
only assessed lymph nodes sampled with EBUS-TBNA, not 
all lymph nodes. Therefore, both lymph node stations inac-
cessible by EBUS-TBNA and lymph nodes examined during 
EBUS but not sampled are not included in the analysis. given 
the criteria, set out at the beginning of this study, the lymph 
nodes that were examined during EBUS but not sampled were 
less than 10 mm, PET negative with no abnormal sonographic 
features. This resulted in an average of 1.7 lymph nodes sam-
pled per patient. However, our practice has changed towards 
the later stages of this study, particularly in light of the revised 
European Society of Thoracic Surgeons guidelines on preop-
erative nodal staging in lung cancer.22 These guidelines man-
date the sampling of any lymph nodes measuring greater than 
5 mm during endoscopic assessment, with a minimum of three 
lymph node stations sampled (4R, 7, and 4L). The majority 
of lymph nodes in this study were enlarged or FDg avid. The 
risk stratification model, therefore, can only be applied to such 
lymph nodes and has not been proven in small, PET-negative 
nodes. The authors are committed to ongoing data collection 
and analysis of this risk stratification model in the context of 
our revised practice and systematic nodal sampling. We intend 
to interrogate the effectiveness of this model in small, PET-
negative nodes with further publications planned.
Ultimately, nodal staging pathways will be heavily 
dependent on local expertise and services. This risk stratifi-
cation model provides a mechanism for lung cancer MDTs 
to discuss the risk of false negative EBUS-TBNA sampling 
in cases of enlarged or PET positive lymph nodes but nega-
tive or inadequate EBUS-TBNA pathology. This may aid the 
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decision making with regard to further staging procedures. It 
is dependent on EBUS operators being proficient in the inter-
pretation of sonographic characteristics during EBUS and 
robust reporting of these findings.
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